51,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

Oral cancer is believed to progress through sequential stages of premalignancies to invasive cancer. Once cancer is formed, the prognosis is poor. The 5-year survival rate of less than 50% is one of the worst among major human cancers. One of the essential keys to improving this gloomy prognosis lies in early diagnosis and proper management of premalignant lesions. A central dogma of carcinogenesis is that alteration to critical control genes underlies malignant transformation. A major focus of this thesis was to study early molecular pathways of oral cancer development. We use Loss of…mehr

Produktbeschreibung
Oral cancer is believed to progress through sequential stages of premalignancies to invasive cancer. Once cancer is formed, the prognosis is poor. The 5-year survival rate of less than 50% is one of the worst among major human cancers. One of the essential keys to improving this gloomy prognosis lies in early diagnosis and proper management of premalignant lesions. A central dogma of carcinogenesis is that alteration to critical control genes underlies malignant transformation. A major focus of this thesis was to study early molecular pathways of oral cancer development. We use Loss of Heterozygosity (LOH), a molecular analysis that can detect the phenotypic change of genome and can work on minute archival material. This thesis has not only provided a comprehensive overview of oral cancer and premalignant lesions with description on their etiological factors and clinicopathological features, but also provided data to establish molecular progression models for oral cancers, and has yielded the first evidence that premalignancies with different molecular risks could be managed differently. The results not only provide insight into the mechanism of early cancer development.
Autorenporträt
Catherine F Poh, DDS, PhD, Certified Oral Pathologist: Studied at the University of British Columbia. Associate Professor, the University of British Columbia and a Clinician Scientist of the BC Cancer Agency. She has been actively involved in applying new technologies in the management oral cancer and precancers.